drugset / Trial / NCT04787354

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

NCT04787354 ↗

Phase 3 Recruiting 976 enrolled Hallym University Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).

Timeline

Start
2021-11-01
Primary completion
2024-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 2000 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 —

Indications